Furthermore, pharmacological inhibition of SRC‐1 enhanced the antitumor effect of PD‐L1 antibody in murine CRC models, indicating that SRC‐1 might be an attractive therapeutic target for CRC. Here, SRC is linked to colorectal carcinoma.